Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Regenerative Immunotherapy for Cancer: Transcription Factor Reprogramming of Tumor-Specific T Cells.

Cancers·2025

Same author

T cells lead the charge against solid tumors.

Nature cancer·2024

Same author

Synthetic soldiers: Turning T cells into immortal warriors.

The Journal of experimental medicine·2024

Same author

Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells.

Cancer research communications·2023

Same author

Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade.

Med (New York, N.Y.)·2022

Same author

Fine-tuning T cell function through engineered orthogonal chimeric cytokine receptors.

Cell research·2022

Search research articles

Related Experiment Video

Updated: Jan 6, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Developing neoantigen-targeted T cell-based treatments for solid tumors.

Tori N Yamamoto^1,2,3, Rigel J Kishton^1,2, Nicholas P Restifo^4,5,6

¹Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

Nature Medicine

|October 9, 2019

Summary

This summary is machine-generated.

Neoantigen-targeted T cell immunotherapies show promise for cancer treatment, but challenges remain in solid tumors. Understanding T cell qualities and tumor antigen presentation is key to improving efficacy.

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Related Experiment Videos

Last Updated: Jan 6, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Area of Science:

Immunology
Oncology
Cancer Therapy

Background:

Adoptive transfer of tumor-targeting lymphocytes shows promise in hematological cancers but has limited efficacy in solid epithelial tumors.
Neoantigens, derived from somatic mutations unique to tumor cells, offer a potential strategy for targeted cancer destruction with minimal damage to healthy tissues.

Purpose of the Study:

To review the promise, progress, and challenges of neoantigen-targeted T cell-based immunotherapies for cancer.
To highlight the complexities of targeting neoantigens, including tumor heterogeneity and the biology of neoantigen recognition.

Main Methods:

Review of current literature on neoantigen-targeted T cell therapies.
Analysis of challenges in antigen processing, presentation, and T cell recognition in solid tumors.

Main Results:

Neoantigen targeting holds potential for specific cancer cell destruction.
Significant hurdles exist, including tumor antigen heterogeneity and variability in antigen processing and presentation.
Not all tumor-expressed neoepitopes elicit a functional immune response.

Conclusions:

Improving neoantigen-targeted T cell therapies requires addressing challenges in tumor antigen recognition and T cell function.
Further research is needed to understand and overcome biological barriers for effective solid tumor immunotherapy.